Hostname: page-component-586b7cd67f-tf8b9 Total loading time: 0 Render date: 2024-11-24T08:18:36.569Z Has data issue: false hasContentIssue false
  • English
  • Français

Atypical antipsychotic drugs in dysthymia: placebo controlled studies of amisulpride versus imipramine, versus amineptine

Published online by Cambridge University Press:  16 April 2020

P Boyer  and
Y Lecrubier
P Boyer
Affiliation:
Inserm, Clinique des Maladies Mentales et de L'Encéphale, 100 rue de la Santé, 75014Paris
Y Lecrubier
Affiliation:
Inserm, U302, Hôpiral de la Salpêtrière, Pavilion Clérambault, 47 blvd de l'Hôpital, 75013Paris, France
Get access

Summary

In order to assess the therapeutic efficacy of amisulpride in dysthymic disorder, two randomised double-blind trials were conducted in France. Both studies included outpatients meeting DSM-III-R criteria for primary dysthymia. Cases of double depressed patients with a mild or moderate major depressive episode superimposed to dysthymia were also eligible. The first study of a three-month duration compared amineptine (200 mg/day) to amisulpride (50 mg/day) and placebo. The second study of a six-month duration compared the therapeutic effects of imipramine (100 mg/day) to amisulpride (50 mg/day) and placebo. Results of the intention to treat analysis and of the end-point analysis were compelling and very similar: significant differences were demonstrated for all primary criteria between amisulpride and placebo and between imipramine and placebo but not between amisulpride and imipramine. For both primary criteria and the responder rate (CGI), statistically significant differences were evidenced between amisulpride and placebo and amineptine and placebo. The same differences were evidenced for SANS subscores. Beneficial effects of low doses of amisulpride in chronic depressive condition can therefore be discussed.

Keywords

amisulprideamineptineimipramine dysthymiaplacebo controlled studies
Type
Research Article
Information
European Psychiatry , Volume 11 , Issue S3 , 1996 , pp. 135s - 140s
Copyright
Copyright © Elsevier paris 1996

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Agnoli, Ravizza LTorta, RStudio controllato in doppio cieco nelle sndromi distimiche (amisulpride venus amitriptilina). Atti del 37 congresso nazionale italiano, S.I.P. Roma 6–11 febbraio 1989Google Scholar
Bakish, DLapierre, YDWeinstein, RRitanserin, imipramine and placebo in the treatment of dysthymic disorder. J Clin Psycho-pharmacol 1933; 6:409–15Google Scholar
Boyer, PLecrubier, YNegative symptomatology and therapeutic use of benzamides. In: Langer, SMendlewicz, JRacagni, CNew generation of antipsychotic drugs: novel mechanisms of action. Basel:Karger, 1992a:136–42Google Scholar
Boyer, PLecrubier, YTreatment of dysthymia with low doses of amisulpride versus amineptine. Clin Neuropharmacol 1992b; 15:238CrossRefGoogle Scholar
Boyer, PLecrubier, YPuech, AJDewailly, JAubin, FTreatment of negative symptoms in schizophrenia with amisulpride. Br J Psychiatry 1995; 166:68–72CrossRefGoogle ScholarPubMed
Costa e Silva, JTraitement des dysthymies par de faibles doses d’amisulpride. Etude comparative amisulpride 50 mg versus placebo. Ann Psychiatry 1990; 5:242–9Google Scholar
Gessa, GLDystymia and depressive disorders: dopamine hypothesis. Eur Psychiatry 1996; 11:123–7CrossRefGoogle Scholar
Harrison, WRabkin, JStewart, JWPhenelzine for chronic depression: a study of continuation treatment. J Clinical Psychiaytry 1986; 47:346–9Google ScholarPubMed
Hellerstein, DJYanowitch, PRosenthal, JRandomized double-blind study of fluoxetine versus placebo in treatment of dysthymia. Am J Psychiatry 1993; 150:1169–75Google ScholarPubMed
Kocsis, JHFrances, AMann, JJImipramine for treatment of chronic depression. Psychopharmacol Bull 1985; 21:698–700Google ScholarPubMed
Kocsis, JHFrances, AJImipramine for treatment of chronic depression. Arch Gen Psychiatry 1988; 45:253–7CrossRefGoogle ScholarPubMed
Kocsis, JHTreatment of dysthymia: overview of therapy options. Focus Depression 1993; 4:59–61Google Scholar
Lecrubier, YBoyer, PRein, WPuech, AJThe treatment of dysthymies with a dopaminergic presynaptic blocker. Neuropsychopharmacology 1994; 10:302Google Scholar
Lecrubier, YBoyer, PDopaminergic influence on motivational processes: improving positive and/ or negative symptoms. Eur Neuropsychopharmacol 1995; 5:214–215CrossRefGoogle Scholar
Paykel, ESDepressve symptomatology and response to amitriptyline. Br J Psychiatry 1972; 120:147–56CrossRefGoogle Scholar
Rioux, PEtude comparative DAN 2163 50/10 mg dans le traitement de l’inhibition psychomotrice chez les malades de type psychas-thénique. Rapport DAN 2163 (internal report) 1984Google Scholar
Sokoloff, PGiros, BMartres, MNature 1990; 146–151CrossRefGoogle Scholar
Tassin, JPInterrelations entre les neuromédiateurs impliqués dans la dépression et les antidépresseurs. Encéphale 1994; XX:623–8Google Scholar
Vallejo, JGasto, CCatalan, RDouble-blind study of imipramine versus phenelzine in melancholic and dysthymic disorders. Br J Psychiatry 1987; 161:639–42CrossRefGoogle Scholar
Willner, PMuscat, RPapp, MChronic mild stress induced anhedonia: a realistic animal model of depression. Neurosci Biobehav Rev 1992; 16:525–534CrossRefGoogle ScholarPubMed
Willner, PPharmacology of anhedonia. Eur Neuropsychopharmacol 1995; 5(suppl 3):214CrossRefGoogle Scholar
Submit a response

Comments

No Comments have been published for this article.